Barclays lowered the firm’s price target on 10x Genomics (TXG) to $15 from $18 and keeps an Overweight rating on the shares.Maximize Your ...
10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology and to advance human health. Cited in more than 7,000 research ...
Zacks.com on MSN2d
10x Genomics (TXG) Reports Q4 Loss, Tops Revenue EstimatesGenomics (TXG) delivered earnings and revenue surprises of -25% and 0.03%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
PLEASANTON, Calif. AP) — 10x Genomics Inc. TXG) on Wednesday reported a loss of $49 million in its fourth quarter.
Genomics reported a Q4 EPS loss of $(0.40), missing estimates, while revenue declined 10% year over year. Analysts lowered price targets amid profitability concerns.
The market expects 10x Genomics (TXG) to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended December 2024. This widely-known consensus ...
Hosted on MSN4mon
These Stocks Moved the Most Today: Tesla, Super Micro, AMD, and MoreSuper Micro Computer declined 1.7% to $46.47 ... The company also launched its latest data center AI chip. 10x Genomics fell 25% after the life-sciences technology company said it expects third ...
Our facility is equipped with state-of-art instruments, including the 10X Genomics Chromium X which enables high-throughput single cell gene expression profiling, 10X Genomics Xenium platform, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback